Northrop Grumman Corp /De/
—- Market cap
- —
- Debt
- +$15.70B
- Cash
- −$4.40B
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NOC stock price vs DHR: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at DHR's multiple
Needs DHR P/E.
Implied fair value · at NOC's multiple
Needs NOC P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth lag
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Eight period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NORTHROP GRUMMAN CORP /DE/ · implied price per share
Bear
$125.92
Base
$162.13
Bull
$209.29
DANAHER CORPORATION · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
Lockheed Martin Corporation
NOC vs LMT
The Boeing Company
NOC vs BA
GENERAL DYNAMICS CORP
NOC vs GD
L3HARRIS TECHNOLOGIES, INC. /DE/
NOC vs LHX
AGILENT TECHNOLOGIES, INC.
NOC vs A
ILLUMINA, INC.
NOC vs ILMN
JOHNSON & JOHNSON
NOC vs JNJ
ABBOTT LABORATORIES
NOC vs ABT
LOEWS CORP
NOC vs L
BERKSHIRE HATHAWAY INC
NOC vs BRK-B
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe NOC can sustain its higher ROIC while materially improving margins toward DHR-like levels, then consider the stock; otherwise, the data favor caution because the current price is far above the DCF range and NOC’s profitability and leverage profile remain weaker than DHR’s.
At $544.40, NOC trades well above its DCF range of $201.83-$273.06 and near the upper end of its historical band of $489.96-$598.84, yet the implied P/E-based price of $1,061.28 assumes a rerating that is not clearly justified by the operating data. On a relative basis, NOC looks cheaper than DHR on P/E and P/S, but that discount reflects materially lower profitability and much thinner margins.
Supporting Metrics